Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 2/2013

01.04.2013 | RHINITIS (JN BARANIUK AND JJ OPPENHEIMER, SECTION EDITORS)

New Directions in Immunotherapy

verfasst von: Linda Cox, Enrico Compalati, Thomas Kundig, Mark Larche

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Allergen immunotherapy (AIT) is effective in reducing the clinical symptoms associated with allergic rhinitis, asthma and venom-induced anaphylaxis. Subcutaneous (SCIT) and sublingual immunotherapy (SLIT) with unmodified allergen extracts are the most widely prescribed AIT regimens. The efficacy of these 2 routes appears comparable, but the safety profile with SLIT is more favorable allowing for home administration and requiring less patient time. However, both require that the treatment is taken regularly over several years, e.g., monthly in a supervised medical setting with SCIT and daily at home with SLIT. Despite the difference in treatment settings, poor adherence has been reported with both routes. Emerging evidence suggests that AIT may be effective in other allergic conditions such as atopic dermatitis, venom sting-induced large local reactions, and food allergy. Research with oral immunotherapy (OIT) for food allergies suggest that many patients can be desensitized during treatment, but questions remain about whether this can produce long term tolerance. Further studies are needed to identify appropriate patients and treatment regimens with these conditions. Efforts to develop safer and more effective AIT for inhalant allergies have led to investigations with modified allergens and alternate routes. Intralymphatic (ILIT) has been shown to produce long-lasting clinical benefits after three injections comparable to a 3-year course of SCIT. Epicutaneous (EPIT) has demonstrated promising results for food and inhalant allergies. Vaccine modifications, such as T cell epitopes or the use of viral-like particles as an adjuvant, have been shown to provide sustained clinical benefits after a relatively short course of treatment compared to the currently available AIT treatments, SLIT and SCIT. These newer approaches may increase the utilization and adherence to AIT because the multi-year treatment requirement of currently available AIT is a likely deterrent for initiating and adhering to treatment.
Literatur
1.
Akinbami LJ, Moorman JE, Bailey C. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS data brief, no 94. Hyattsville: National Center for Health Statistics; 2012.
2.
Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol. 2011;127:145–52.PubMedCrossRef
3.
Wallace D, Dykewicz M, Bernstein D, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allerg Clin Immunol. 2008;122:S1–S84.CrossRef
4.
5.
Schoenwetter WF, Dupclay Jr L, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305–17.PubMedCrossRef
6.
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–25 e5. Study demonstrating the persistent efficacy of SLIT after treament discontinuation.PubMedCrossRef
7.
Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126:969–75.PubMedCrossRef
8.
Hankin CS, Cox L, Wang Z, Bronstone A. Does Allergen-specific immunotherapy provide cost benefits for children and adults with allergic rhinitis? Results from large-scale retrospective analyses jointly funded by AAAAI and ACAAI. J Allerg Clin Immunol. 2011;127:AB73.CrossRef
9.
• Lockey RF, Hankin CS. Health economics of allergen-specific immunotherapy in the United States. J Allergy Clin Immunol. 2011;127:39–43. Brief but fairly complete review of the cost-efficacy of AIT.PubMedCrossRef
10.
Strunk RC, Sternberg AL, Szefler SJ, Zeiger RS, Bender B, Tonascia J. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr. 2009;154:682–7.PubMedCrossRef
11.
Ariano R, Berto P, Tracci D, Incorvaia C, Frati F. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc. 2006;27:159–63.PubMed
12.
Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–8.PubMedCrossRef
13.
Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61:198–201.PubMedCrossRef
14.
Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131–8 e1-7.PubMedCrossRef
15.
Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103:451–9. quiz 9-61, 95.PubMedCrossRef
16.
• Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol. 2010;126:668–9. Study demonstrates the relatively poor compliance with SLIT in ‘real-life’ studies.PubMedCrossRef
17.
Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121:227–32.PubMedCrossRef
18.
Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. International forum of allergy & rhinology 2012;2:280–4.
19.
• Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol. 2012;23:688–9. Demonstrates poor compliance with SLIT in the very young pediatric population.PubMedCrossRef
20.
Pajno GB, Vita D, Caminiti L, et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol. 2005;116:1380–1.PubMedCrossRef
21.
Rotiroti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol. 2012;130:918–24 e1.PubMedCrossRef
22.
Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? Journal of controlled release. 2010;148:266–82.
23.
Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679–91.PubMed
24.
Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9:165–9.PubMedCrossRef
25.
Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol. 2007;8:11–3.PubMedCrossRef
26.
Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in search of the 'epimmunome'. Nat Immunol. 2010;11:656–65.PubMedCrossRef
27.
Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol. 2012;132:1326–9.PubMedCrossRef
28.
Gilliet M, Soumelis V, Watanabe N, et al. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. J Exp Med. 2003;197:1059–63.PubMedCrossRef
29.
Savinko T, Matikainen S, Saarialho-Kere U, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol. 2012;132:1392–400.PubMedCrossRef
30.
31.
Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673–80.PubMedCrossRef
32.
Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;1:1572–3.CrossRef
33.
Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986;16:483–91.PubMedCrossRef
34.
Tucker MH, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol. 2008;101:419–25.PubMedCrossRef
35.
Sikora JM, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists in the United States. Ann Allergy Asthma Immunol 2013; in press.
36.
Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008;100:475–81.PubMedCrossRef
37.
Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3):660–6
38.
Creticos P, Esch R, Couroux P, Gentile D, Angelo P, Whitlow B, et al. A Randomized, Double-Blind, Placebo-Controlled, Parallel Trial of Standardized Short Ragweed Sublingual Allergy Immunotherapy Liquid Extract in Adult Subjects with Ragweed-Induced Allergic Rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2013;abstract in press.
39.
Creticos P, Maloney J, Nolte H, Creticos P, Maloney J, Nolte H, et al. Efficacy and safety of a novel ragweed Allergy Immunotherapy Tablet (AIT) during peak season in North America. J Allerg Clin Immunol. 2012;129:AB143.CrossRef
40.
Maloney J, Nolte H, Nekam K, et al. Dose-related effects of ragweed allergy immunotherapy tablet on nasal and ocular symptoms of allergic rhinoconjunctivitis during the peak ragweed pollen seasons in Europe and North America. J Allerg Clin Immunol. 2012;129:AB47.CrossRef
41.
Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011;127(64–71):e1–4.PubMed
42.
Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(6):1327–34
43.
Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127(72–80):e1–2.
44.
Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124(1):150–6. e1–5. Epub 2009/06/16.PubMedCrossRef
45.
Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;130(1):215–24 e7ne
46.
Bush RK, Swenson C, Fahlberg B, Evans MD, Esch R, Morris M, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol. 2011;127(4):974-81 e1–7.
47.
Wood R. Immunologic effects of cockroach specific immunotherapy AAAAI annual meeting presentation. 2012.
48.
Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7:542–6.PubMedCrossRef
49.
Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006;118(6):1292–8.
50.
•• Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012;12:427–33. Systematic review of AIT for atopic dermatitis indicating that the data are conflicting in terms of the efficacy of this treatment for this condition and underscoring the need for further studies.PubMedCrossRef
51.
Novak N, Thaci D, Hoffmann M, et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract–a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol. 2011;155:252–6.PubMedCrossRef
52.
Novak N, Bieber T, Hoffmann M, Folster-Holst R, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130(4):925–31
53.
Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164–70.PubMedCrossRef
54.
Immune Tolerance Network. Promoting tolerance to common allergens in high-risk children: Global Prevention of Asthma in Children (GPAC) Study. ClinicalTrials.gov Identifier:NCT00346398.
55.
Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99:744–51.PubMedCrossRef
56.
Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–62.PubMedCrossRef
57.
Patriarca C, Romano A, Venuti A, et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol (Madr). 1984;12:275–81.
58.
Patriarca G, Nucera E, Roncallo C, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther. 2003;17:459–65.PubMedCrossRef
59.
Patriarca G, Buonomo A, Roncallo C, et al. Oral desensitisation in cow milk allergy: immunological findings. Int J Immunopathol Pharmacol. 2002;15:53–8.PubMed
60.
Buchanan AD, Green TD, Jones SM, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119:199–205.PubMedCrossRef
61.
Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105:444–50.PubMedCrossRef
62.
Itoh N, Itagaki Y, Kurihara K. Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up. Allergol Int. 2010;59:43–51.PubMedCrossRef
63.
Garcia Rodriguez R, Urra JM, Feo-Brito F, et al. Oral rush desensitization to egg: efficacy and safety. Clin Exp Allergy. 2011;41:1289–96.PubMedCrossRef
64.
Meglio P, Giampietro PG, Carello R, Gabriele I, Avitabile S, Galli E. Oral food desensitization in children with IgE-mediated hen's egg allergy: a new protocol with raw hen's egg. Pediatr Allergy Immunol. 2012 Aug 13.
65.
Fuentes-Aparicio V, Alonso-Lebrero E, Zapatero L, Infante S, Lorente R, Angeles Munoz-Fernandez M, et al. Oral immunotherapy in hen's egg-allergic children increases a hypo-proliferative subset of CD4+ T cells that could constitute a marker of tolerance achievement. Pediatr Allergy Immunol. 2012;23(7):648–53.
66.
Dello Iacono I, Tripodi S, Calvani M, Panetta V, Verga MC, Miceli Sopo S. Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: A randomized controlled trial. Pediatr Allergy Immunol. 2012 Sep 9.
67.
•• Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367:233–43. Well-designed study examining the efficacy and safety of egg OIT, showing that most can be desensitized but most do not achieve long-term tolerance.PubMedCrossRef
68.
Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy. 2004;59:980–7.PubMedCrossRef
69.
Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007;62:1261–9.PubMedCrossRef
70.
Staden U, Blumchen K, Blankenstein N, et al. Rush oral immunotherapy in children with persistent cow's milk allergy. J Allerg Clin Immunol. 2008;122:418–9.CrossRef
71.
Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008;121:343–7.PubMedCrossRef
72.
Martorell Aragones A, Felix Toledo R, Cerda Mir JC, Martorell Calatayud A. Oral rush desensitization to cow milk. Following of desensitized patients during three years. Allergologia et Immunopathologia. 2007;35:174–6.PubMedCrossRef
73.
Pajno GB, Caminiti L, Ruggeri P, et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105:376–81.
74.
Skripak JM, Nash SD, Rowley H, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122:1154–60.PubMedCrossRef
75.
Morisset M, Moneret-Vautrin DA, Guenard L, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol. 2007;39:12–9.PubMed
76.
Zapatero L, Alonso E, Fuentes V, Martinez MI. Oral desensitization in children with cow's milk allergy. J Investig Allergol Clin Immunol. 2008;18:389–96.PubMed
77.
•• Brozek JL, Terracciano L, Hsu J, et al. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2012;42:363–74. Systematic review that concluded that the “potentially large benefit of oral immunotherapy in patients with cow's milk allergy may be counterbalanced by frequent and sometimes serious adverse effects”.PubMedCrossRef
78.
Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. Allergy. 2009;64:1218–20.PubMedCrossRef
79.
Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(292–300):e1–e97.
80.
Blumchen K, Ulbricht H, Staden U, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126:83–91. e1.PubMedCrossRef
81.
Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy. 2011;41:1273–81.PubMedCrossRef
82.
Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654–60.PubMedCrossRef
83.
•• Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev. 2012;9:CD009014. Systematic review that concluded that “in view of the risk of adverse events and the lack of evidence of long-term benefits, allergen-specific peanut OIT cannot currently be recommended as a treatment for the management of patients with IgE-mediated peanut allergy”.PubMed
84.
Thyagarajan A, Varshney P, Jones SM, et al. Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin Immunol. 2010;126:31–2.PubMedCrossRef
85.
• Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129:448–55. 55 e1–5. Review of AIT for milk allergy that concluded “OIT was more efficacious for desensitization to CM than SLIT alone but was accompanied by more systemic side effects. Clinical desensitization was lost in some cases within 1 week off therapy”.PubMedCrossRef
86.
Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073–9.PubMedCrossRef
87.
Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64:876–83.PubMedCrossRef
88.
Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127:640–6.PubMedCrossRef
89.
Kulis M, Saba K, Kim EH, et al. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. J Allergy Clin Immunol. 2012;129:1159–62.PubMedCrossRef
90.
Mauro M, Russello M, Incorvaia C, et al. Birch-apple syndrome treated with birch pollen immunotherapy. Int Arch Allergy Immunol. 2011;156:416–22.PubMedCrossRef
91.
Nucera E, Aruanno A, Rizzi A, et al. Profilin desensitization in two patients with plant-derived food allergy. Int J Immunopathol Pharmacol. 2012;25:531–5.PubMed
92.
Cortellini G, Spadolini I, Santucci A, et al. Improvement of shrimp allergy after sublingual immunotherapy for house dust mites: a case report. Eur Ann Allergy Clin Immunol. 2011;43:162–4.PubMed
93.
Patriarca G, Nucera E, Roncallo C, et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol. 2008;21:669–77.PubMed
94.
Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2008;122(1):44–8.
95.
96.
Frech SA, Dupont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet. 2008;371:2019–25.PubMedCrossRef
97.
Frerichs DM, Ellingsworth LR, Frech SA, et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine. 2008;26:2782–7.PubMedCrossRef
98.
Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915–20.
99.
Enfield J, O'Connell ML, Lawlor K, Jonathan E, O'Mahony C, Leahy M. In-vivo dynamic characterization of microneedle skin penetration using optical coherence tomography. J Biomed Opt. 2010;15:046001.PubMedCrossRef
100.
Fernando GJ, Chen X, Prow TW, et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One. 2010;5:e10266.
101.
Haq MI, Smith E, John DN, et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices. 2009;11:35–47.PubMedCrossRef
102.
Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol. 2012;351:77–112.PubMedCrossRef
103.
van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Contr Rel Offic J Contr Rel Soc. 2012;161:645–55.CrossRef
104.
Vrdoljak A, McGrath MG, Carey JB, et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Contr Rel Offic J Contr Rel Soc. 2012;159:34–42.CrossRef
105.
Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest. 1992;90:482–7.PubMedCrossRef
106.
Tan G, Xu P, Lawson LB, et al. Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules. J Pharm Sci. 2010;99:730–40.PubMed
107.
Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125:1165–7.PubMedCrossRef
108.
Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40:659–67.PubMedCrossRef
109.
Eyler JM. Smallpox in history: the birth, death, and impact of a dread disease. J Lab Clin Med. 2003;142:216–20.PubMedCrossRef
110.
Frech SA, Kenney RT, Spyr CA, et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine. 2005;23:946–50.PubMedCrossRef
111.
Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, Clements CJ. Ensuring vaccine safety in immunization programmes–a WHO perspective. Vaccine. 2001;19:1594–605.PubMedCrossRef
112.
Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines. 2003;2:253–67.PubMedCrossRef
113.
Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature. 1998;391:851.PubMedCrossRef
114.
Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol. 1998;161:3211–4.PubMed
115.
Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med. 2000;6:1403–6.PubMedCrossRef
116.
Phillips EW. Relief of hay-fever by intradermal injections of pollen extract. JAMA. 1926;86:182–4.CrossRef
117.
Hurwitz SH. Medicine: seasonal hay fever-some problems in treatment. Cal West Med. 1930;33:520–1.PubMed
118.
Vallery-Radot P, Hangenau J. Asthme d'origine équine. Essai de désensibilisation par des cutiréactions répétées. Bull Soc Méd Hôp Paris. 1921;45:1251–60.
119.
Pautrizel R, Cabanieu G, Bricaud H, Broustet P. Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route. Sem Hop. 1957;33:1394–403.PubMed
120.
Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. Presse Med. 1959;67:2299–301.PubMed
121.
Blamoutier P, Blamoutier J, Guibert L. Traitement co-saisonnier de la pollinose par l'application d'extraits de pollens sur des quadrillages cutanés. Revue Francaise d'Allergie. 1961;1:112–20.CrossRef
122.
Eichenberger H, Storck H. Co-seasonal desensitization of pollinosis with the scarification-method of Blamoutier. Acta Allergol. 1966;21:261–7.PubMedCrossRef
123.
Martin-DuPan R, Buser F, Neyroud M. Treatment of pollen allergy using the cutaneous checker square method of Blamoutier and Guibert. Schweiz Rundsch Med Prax. 1971;60:1469–72.PubMed
124.
Palma-Carlos A-G. Traitement co-saisonnier des pollinoses au Portugal par la méthode des quadrillages cutanés. Revue Francaise d'Allergie. 1967;7:92–5.CrossRef
125.
Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002.PubMedCrossRef
126.
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129:128–35. EPIT dose-response study that demonstrated that EPIT can be effective in treating grass-induced allergic rhinitis.PubMedCrossRef
127.
Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy. 2010;65:410–1.PubMedCrossRef
128.
Johansen P, Mohanan D, Martinez-Gomez JM, Kundig TM, Gander B. Lympho-geographical concepts in vaccine delivery. J Contr Rel Offic J Contr Rel Soc. 2010;148:56–62.CrossRef
129.
Kündig TM, Johansen P, Senti G. Intralymphatic vaccination. In: Rapuolli R, Bagnoli F, editors. Vaccine design. Norfolk: Caister Academic Press; 2011. p. 211–24.
130.
Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9:537–43.PubMedCrossRef
131.
Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71–84.PubMedCrossRef
132.
von Moos S, Kundig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011;31(2):391–406.
133.
Johansen P, Senti G, Martinez Gomez JM, et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy. 2005;35:1591–8.PubMedCrossRef
134.
Johansen P, Senti G, Martinez Gomez JM, Wuthrich B, Bot A, Kundig TM. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol. 2005;35:3591–8.PubMedCrossRef
135.
Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150:59–65.PubMedCrossRef
136.
Martinez-Gomez JM, Johansen P, Rose H, et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy. 2009;64:172–8.PubMedCrossRef
137.
Mohanan D, Slutter B, Henriksen-Lacey M, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Contr Rel Offic J Contr Rel Soc. 2010;147:342–9.CrossRef
138.
Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105:17908–12.PubMedCrossRef
139.
140.
Siegrist CA. The immunology of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia: Elsevier Inc; 2008. p. 17–36.
141.
Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol; 2013: in press.
142.
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–6. Demonstrated the effectiveness of ILIT in treating cat allergy.PubMedCrossRef
143.
Bolhaar ST, Zuidmeer L, Ma Y, et al. A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebocontrolled food challenge. Clin Exp Allergy 2005;35:1638–44.
144.
Burks AW, King N, Bannon GA. Modification of a major peanut allergen leads to loss of IgE binding. Int Arch Allergy Immunol 1999;118:313–4.
145.
Drew AC, Eusebius NP, Kenins L, et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004;173:5872–9.
146.
Ferreira F, Ebner C, Kramer B, et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998;12:231–42.
147.
Ferreira F, Rohlfs A, Hoffmann-Sommergruber K, et al. Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis. Adv Exp Med Biol. 1996;409:127–35.PubMedCrossRef
148.
Okada T, Swoboda I, Bhalla PL, Toriyama K, Singh MB. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett 1998;434:255–60.
149.
Rabjohn P, West CM, Connaughton C, et al. Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation. Int Arch Allergy Immunol 2002;128:15–23.
150.
Stanley JS, King N, Burks AW, et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Archives of biochemistry and biophysics 1997;342:244–53.
151.
Swoboda I, Bugajska-Schretter A, Linhart B, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 2007;178:6290–6.
152.
Swoboda I, De Weerd N, Bhalla PL, et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002;32:270–80.
153.
Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14677–82.
154.
Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003;111:854–61.
155.
Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol 2012;12:555–63.
156.
Larche M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006;18:745–50.
157.
Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–13.PubMedCrossRef
158.
Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122:951–60.PubMedCrossRef
159.
Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 2001;15(11):2045–7.
160.
Vrtala S, Hirtenlehner K, Vangelista L, et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest. 1997;99:1673–81.PubMedCrossRef
161.
Egger C, Horak F, Vrtala S, Valenta R, Niederberger V. Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses. J Allergy Clin Immunol. 2010;126:1312–5. e4.PubMedCrossRef
162.
Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy. 2010;40:1346–52.PubMedCrossRef
163.
Reisinger J, Horak F, Pauli G, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005;116:347–54.PubMedCrossRef
164.
Gafvelin G, Thunberg S, Kronqvist M, et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol. 2005;138:59–66.PubMedCrossRef
165.
Purohit A, Niederberger V, Kronqvist M, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy. 2008;38:1514–25.PubMedCrossRef
166.
van Hage-Hamsten M, Kronqvist M, Zetterstrom O, et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969–77.
167.
Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M, et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol. 2007;119(4):1013–6.
168.
Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006;117:1470–6.PubMedCrossRef
169.
• Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39:562–70. Study evaluated a virus-like particle as an adjuvant for dust mite AIT.
170.
Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy. 1987;17:459–68.PubMedCrossRef
171.
Edlmayr J, Niespodziana K, Linhart B, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol. 2009;182:6298–306.PubMedCrossRef
172.
Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93:222–31.PubMedCrossRef
173.
Norman PS, Ohman Jr JL, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623–8.PubMed
174.
Pene J, Desroches A, Paradis L, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol. 1998;102:571–8.PubMedCrossRef
175.
Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol. 1996;8:1937–45.PubMedCrossRef
176.
Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999;189:1885–94.PubMedCrossRef
177.
Haselden BM, Syrigou E, Jones M, et al. Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. J Allergy Clin Immunol. 2001;108:349–56.PubMedCrossRef
178.
Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy. 2005;60:1269–74.PubMedCrossRef
179.
Alexander C, Ying S, A BK, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005;35(1):52–8.
180.
Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol. 2001;167:1734–9.PubMed
181.
Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360:47–53.PubMedCrossRef
182.
Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy. 2004;59:1097–101.PubMedCrossRef
183.
Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med. 2005;2:e78.PubMedCrossRef
184.
Campbell JD, Buckland KF, McMillan SJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009;206:1535–47.PubMedCrossRef
185.
• Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127:89–97. e1–14. Demonstrated that one administration of aT cell epitope vaccine suppressed late-phase skin reactions.PubMedCrossRef
186.
• Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. J Allergy Clin Immunol 2012. Demonstrates the efficacy andsafety of petide immunotherapy with a modified cat vaccine.
187.
Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124:471–7. 7 e1.PubMedCrossRef
188.
Berkowitz RB, Braker S, Lutz C, et al. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96:327–33.PubMedCrossRef
189.
Carballido JM, Carballido-Perrig N, Kagi MK, et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993;150:3582–91.
190.
Muller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101:747–54.PubMedCrossRef
191.
Texier C, Pouvelle S, Busson M, et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol. 2000;164:3177–84.PubMed
192.
Tarzi M, Klunker S, Texier C, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36:465–74.PubMedCrossRef
193.
de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy. 2006;61:1238–9.PubMedCrossRef
Metadaten
Titel
New Directions in Immunotherapy
verfasst von
Linda Cox
Enrico Compalati
Thomas Kundig
Mark Larche
Publikationsdatum
01.04.2013
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 2/2013
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-012-0335-7

Weitere Artikel der Ausgabe 2/2013

Current Allergy and Asthma Reports 2/2013 Zur Ausgabe

SINUSITIS (ML KOWALSKI, SECTION EDITOR)

Oral Steroid Therapy in Chronic Rhinosinusitis with and without Nasal Polyposis

SINUSITIS (ML KOWALSKI, SECTION EDITOR)

Role of Fungi in the Pathophysiology of Chronic Rhinosinusitis: An Update

RHINITIS (JN BARANIUK AND JJ OPPENHEIMER, SECTION EDITORS)

The Role of Interleukin-33 in Rhinitis

RHINITIS (JN BARANIUK AND JJ OPPENHEIMER, SECTION EDITORS)

Fungal Disease of the Nose and Sinuses: An Updated Overview

SINUSITIS (ML KOWALSKI, SECTION EDITOR)

Nasal Saline Irrigations for the Symptoms of Acute and Chronic Rhinosinusitis

RHINITIS (JN BARANIUK AND JJ OPPENHEIMER, SECTION EDITORS)

Impact of Sleep as a Specific Marker of Quality of Life in Allergic Rhinitis

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise